Adagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conference

Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a prominent innovator in catheter ablation technologies, has announced its participation in the TD Cowen 46th Annual Healthcare Conference. Scheduled for March 3, 2026, at 2:30 PM ET in Boston, the company's management will showcase their advancements in medical device technology aimed at treating cardiac arrhythmias. A live webcast of the presentation will be available on the company's investor relations website and a dedicated event page.

Adagio Medical specializes in developing and commercializing innovative products that utilize its proprietary Ultra-Low Temperature Cardiac (ULTA) ablation technology. This cutting-edge approach enables the creation of significant and durable lesions that extend deep into both diseased and healthy cardiac tissues. The company's primary focus is the treatment of ventricular arrhythmias through its vCLAS™ Cryoablation System, which has received CE Mark approval and is currently undergoing evaluation in the FULCRUM-VT U.S. Pivotal IDE Trial.

FULCRUM-VT is a prospective, multi-center trial assessing the feasibility of ULTA Cryoablation for recurring monomorphic ventricular tachycardia (VT). The study has successfully enrolled 209 patients with structural heart disease, including those with ischemic and non-ischemic cardiomyopathy, and aims to provide data for FDA premarket approval (PMA) for the vCLAS™ system. The trial results could pave the way for the most comprehensive industry indication for endocardial ablation of scar-mediated VT.

While the vCLAS™ Cryoablation System is commercially available for treating monomorphic VT in Europe and select areas, it remains investigational in the U.S. Adagio Medical's innovations present a promising advancement in the field of cardiac care, potentially enhancing treatment options for patients with challenging arrhythmias.

As Adagio Medical prepares to present at the TD Cowen 46th Annual Healthcare Conference, investors have an important opportunity to assess the company’s strategic position and potential growth trajectory in the innovative space of catheter ablation technologies for cardiac arrhythmias.

Adagio’s Ultra-Low Temperature Cardiac (ULTA) ablation technology offers a competitive edge. The capacity to create large and durable lesions through both diseased and healthy cardiac tissue showcases a significant advancement in the treatment of ventricular arrhythmias, particularly through their vCLAS™ Cryoablation System. With regulatory strides such as the CE Mark approval for European markets, the company is poised to tap into lucrative international revenue streams. The system’s pending status in the U.S., pending the results of the FULCRUM-VT trial, adds a layer of anticipation to its valuation. Successful trial outcomes could bolster FDA approval prospects, paving the way for a significant market presence in the U.S.

The FULCRUM-VT trial, focusing on drug-refractory ventricular tachycardia, has fully enrolled 209 patients, indicating strong clinical interest and potential regulatory momentum. Given the escalating prevalence of cardiac arrhythmias within aging populations, the demand for effective treatment options is expected to grow.

However, investors should maintain a cautious perspective. The dependence on trial outcomes introduces volatility and uncertainty into Adagio's investment narrative. As the company awaits pivotal results, those considering an investment might benefit from a phased approach—monitoring the developments closely while assessing risk tolerance.

In summary, while Adagio Medical holds promise with its innovative technologies and pivotal clinical efforts, investors should weigh the potential rewards against the inherent risks associated with clinical trials and regulatory approval processes. Keeping a vigilant eye on upcoming presentations and trial results will be crucial for informed decision-making.